Cancer and cardiovascular disease (CVD) are the two most common causes of mortality and morbidity worldwide. It has been estimated that 17.7 million people die annually as a consequence of cardiovascular diseases, whereas cancer accounts for 8.8 million deaths per year. Evidence linking cardiovascular diseases with a higher incidence of cancer has been suggested previously in many clinical trials and animal experiments. Emerging literature suggests that modifiable risk factors including diet, sedentary lifestyle, obesity, and tobacco use are central to the pathogenesis of both diseases and are reflected in common genetic, cellular, and signaling mechanisms. Understanding this important biological overlap is critical and may help identify novel therapeutic and preventative strategies for both disorders.

Extensive knowledge has already been gained concerning cancer treatment-related cardiotoxicity, although the molecular mechanism and medical practice are largely unknown and need further in-depth investigation. In addition, the common pathological factors underlying CVD and CVD-related cancers have not been fully explored. Several prediction models taking into account the full spectrum of late effects are needed to guide primary treatment choice and appropriate follow-up after cancer treatment. Although a growing body of evidence supports a role for aspirin, statins, ACE inhibitors/ARBs, metformin, and TZDs in cancer prevention and CVD treatment, it remains of outstanding interest to design, develop, and validate the pharmacologic and non-pharmacologic preventive approaches for the treatment of CVD and CVD-related cancers.

The goal of this Special Issue is to understand the recent advances in the clinical treatment and management of CVD and CVD-related cancers. We invite authors to submit original research and review articles that will stimulate the continuing efforts in elucidating the epidemiology, diagnostic strategies, therapeutic approaches, preventive models, and prognostic analysis of CVD and CVD-related cancers.

Potential topics include but are not limited to the following:

• Molecular mechanisms and diagnostic strategies of CVD-related cancers, such as breast cancer, lung cancer, and hematologic tumors
• Clinical features of patients with severe CVD or CVD-related cancers
• Circulating biomarkers in the diagnosis and prognostic analysis of CVD or cancers-related CVD
• Recent advances in medical imaging in patients with CVD or CVD-related cancers
• Pharmacologic and non-pharmacologic preventive approaches for the treatment of CVD and CVD-related cancers
• Statistical models in the early diagnosis, rapid detection, and efficacy evaluation of patients with CVD or CVD-related cancers